Brücher B L, Stein H J, Bartels H, Feussner H, Siewert J R
Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universität, Ismaninger Strasse 22, 81675 München, Germany.
World J Surg. 2001 Jun;25(6):745-9. doi: 10.1007/s00268-001-0026-3.
Reported incidence rates of carcinoma in patients with achalasia and the prevalence of achalasia in patients with esophageal cancer vary widely in the literature. The prognosis of an "achalasia-carcinoma" is generally considered poor, although systematic studies assessing the incidence, prevalence, and prognosis of patients with "achalasia-carcinoma" are scant. We investigated the incidence of esophageal cancer in a large series of patients with known achalasia, assessed the prevalence of achalasia in patients presenting with esophageal cancer, and evaluated the prognosis of these patients compared to that of patients with esophageal cancer without achalasia. Between 1982 and 1998 a total of 124 patients with primary achalasia were treated and followed at our department. During the same time period 1366 patients presented with esophageal cancer (879 esophageal squamous cell carcinomas, 487 adenocarcinomas). Of the 124 patients with primary achalasia, 4 developed a carcinoma during a mean follow-up of 5.6 years (i.e., an incidence of one carcinoma per 173.6 patient-years of follow-up). Altogether, 13 of 879 patients (1.5%) presenting with esophageal squamous cell carcinoma and 1 of 487 patients (0.2%), presenting with esophageal adenocarcinoma had a history of primary achalasia. Seven patients with achalasia-carcinoma (50%) had early-stage disease (stage I, IIA, or IIB). There was no difference in the prognosis of patients with resected achalasia-carcinoma versus those with esophageal carcinoma but no achalasia. Thus in our population of patients with long-standing achalasia the risk for developing an esophageal cancer was increased about 140-fold over that of the general population. With liberal use of surveillance, carcinoma could often be detected at an early stage in these patients, with a prognosis that was not worse than that of patients with squamous cell esophageal cancer but no achalasia.
在文献中,贲门失弛缓症患者的癌症报告发病率以及食管癌患者中贲门失弛缓症的患病率差异很大。尽管评估“贲门失弛缓症-癌”患者发病率、患病率和预后的系统研究很少,但“贲门失弛缓症-癌”的预后通常被认为很差。我们调查了一大系列已知患有贲门失弛缓症患者的食管癌发病率,评估了食管癌患者中贲门失弛缓症的患病率,并与无贲门失弛缓症的食管癌患者相比,评估了这些患者的预后。1982年至1998年期间,我们科室共治疗并随访了124例原发性贲门失弛缓症患者。在同一时期,有1366例患者被诊断为食管癌(879例食管鳞状细胞癌,487例腺癌)。在124例原发性贲门失弛缓症患者中,4例在平均5.6年的随访期间发生了癌症(即每173.6患者-年的随访中有1例癌症发生)。在879例食管鳞状细胞癌患者中,共有13例(1.5%)有原发性贲门失弛缓症病史;在487例食管腺癌患者中,有1例(0.2%)有原发性贲门失弛缓症病史。7例贲门失弛缓症-癌患者(50%)处于疾病早期(I期、IIA期或IIB期)。切除的贲门失弛缓症-癌患者与无贲门失弛缓症的食管癌患者的预后没有差异。因此,在我们的长期贲门失弛缓症患者群体中,发生食管癌的风险比普通人群增加了约140倍。通过广泛应用监测,这些患者的癌症通常能在早期被发现,其预后并不比无贲门失弛缓症的食管鳞状细胞癌患者差。